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Abstract Alzheimer's disease (AD) is pathologically charac-
terized by deposition of β-amyloid (Aβ) peptides, which
closely correlates with the balance of nerve growth factor
(NGF)-related TrkA/p75NTR signaling. (−)-Epigallocatechin-
3-gallate (EGCG) is used for prevention and treatment of
many neurodegenerative diseases, including AD. However,
whether the neuroprotective effects of EGCG treatment were
via modulating the balance of TrkA/p75NTR signaling was still
unknown. In this study, we found that EGCG treatment
(2 mg · kg –1 · day –1) dramatically ameliorated the cognitive
impairments, reduced the overexpressions of Aβ(1–40) and
amyloid precursor protein (APP), and inhibited the neuronal
apoptosis in the APP/PS1mice. Interestingly, the EGCG treat-
ment enhanced the relative expression level of NGF by in-
creasing the NGF/proNGF ratio in the APP/PS1 mice.
Moreover, after EGCG treatment, TrkA signaling was activat-
ed by increasing the phosphorylation of TrkA following the
increased phosphorylation of c-Raf, ERK1/2, and cAMP re-
sponse element-binding protein (CREB), simultaneously the
p75NTR signaling was significantly inhibited by decreasing the
p75ICD expression, JNK2 phosphorylation, and cleaved-
caspase 3 expression, so that the Aβ deposits and neuronal
apoptosis in the hippocampus were inhibited.
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Introduction
Alzheimer's disease (AD), an age-related neurodegenerative
disorder, is the predominant form of dementia in the elderly.
AD is clinically characterized by cognitive impairment and
pathologically characterized by extracellular senile plaques
largely composed of β-amyloid (Aβ) peptide and neuronal
loss [1–3]. The abnormal accumulation of Aβ generated by
successive proteolysis of β-amyloid precursor protein (APP)
causes the neurotoxic effects by oxidative stress, calcium
overburden, and neuronal apoptosis in vitro and in vivo, and
is one of the main neuropathological hallmarks of AD [4–8].
The decreased activity of cell survival and neuronal apoptosis
is the final destiny of neurons in AD and other neurodegener-
ative diseases. Nerve growth factor (NGF), the first
neurotrophin known for its stimulatory effects on differentia-
tion, maintenance, survival, and plasicity of brain function,
elicits most of the survival and growth properties mediated by
activating the tyopomyosin kinase receptor A (Trk A) related
signaling pathway and inhibiting the p75 neurotrophin recep-
tor (p75NTR) related signaling pathway [9–13]. It was reported
that the NGF deficiency would lead to a TrkA/p75NTR imbal-
ance in AD brain, which might be one of possible mechanisms
of neurodegeneration. When NGF was deficient in AD brain,
the TrkA-related signaling was inhibited and the p75NTR-
related signaling was activated concurrently. Then, the
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expression levels of memory-, learning- and apoptosis-related
proteins downstream were affected, and then, the neuronal
degeneration, cell death/loss, and cognitive deficits occurred
[10, 11, 14–16]. Therefore, it is meaningful to find a way to
ameliorate the low expression of NGF and to adjust the
TrkA/p75NTR imbalance in AD brain.
(−)-Epigallocatechin-3-gallate (EGCG) is the most abun-
dant polyphenolic constituent in green tea and was particularly
suggested to have potent ironchelating, antioxidant, anti-
inflammatory, and anticancer effects [17–22]. Previous studies
reported that EGCG treatment significantly reduced Aβ gen-
eration in human-derived neuroblastoma cell line (SH-SY5Y)
induced by 3-HK, in murine neuron-like cells (N2a)
transfected with human “Swedish” mutant APP, and in pri-
mary neurons derived from Swedish mutant APP-
overexpressing mice (TgAPPsw line 2576), and markedly im-
proved the cognitive deficits, APP processing, and Tau pa-
thology in D-gal-induced AD mice, TgAPPsw line 2576 trans-
genic mice and PS2 transgenic mice, suggesting that EGCG
treatment exerted the neuroprotective effects in vitro and
in vivo [23–27]. However, there is no study performed to
evaluate whether EGCG treatment ameliorates cognitive def-
icits in APP/PS1 transgenic mice and, if it does, whether the
ameliorating effect is through regulating the balance of
TrkA/p75NTR signaling. Therefore, in the present study, we
examined the neuroprotective effects of EGCG treatment in
APP/PS1 transgenic mice on the neurodegenerative pathology
and behavioral deficits firstly. Furthermore, the possible neu-
roprotective mechanisms on the balance of NGF-related
TrkA/p75NTR signaling after EGCG treatment in APP/PS1
transgenic mice were investigated.
Methods
Animals and Treatment
APP/PS1 double-transgenic mice were obtained from The
Jackson Laboratory [B6.Cg-Tg (APPswe, PSEN1dE9) 85Dbo/
J]. These mice express a chimeric mouse/human APP containing
the K595N/M596LSwedish mutations and a mutant human PS1
carrying the exon 9-deleted variant under the control of mouse
prion promoter elements, directing transgene expression predom-
inantly to central nervous system (CNS) neurons [28–30]. The
offspring 9-month-old double-transgenic mice overexpressing
APP/PS1 were compared with their wild-type (WT) littermates
so that age and background strain were matched. Males and
females were equally distributed into each group.
All mice were housed in cages in a controlled environment
(22–25 °C, 55 % relative humidity, 12 h light/dark cycle) with
free access to food and water, and maintained in a specific
pathogen-free environment at Laboratory Animal Science of
China Medical University. All animal care and experimental
procedures were in compliance with the Standard Medical
Laboratory Animals' Care and Use Protocols (Ministry of
Health PR China, 1998) and the Laboratory Animal Ethical
Standards of China Medical University.
EGCG (Sigma-Aldrich Chemicals Pvt. Ltd., USA) was dis-
solved into distilled water at a concentration of 0.2 mg/mL.
Distilled water was used as vehicle. EGCG or vehicle was
administered by intragastric administration (2 mg/kg body
weight) at 9:00AM once daily for 4 weeks. Twenty 9-month-old
APP/PS1 transgenic mice were randomly and equally assigned
into two groups, EGCG-treated APP/PS1 group and vehicle-
treated APP/PS1 group (APP/PS1 group), with 10 mice in each
group. Another 10 wild-type littermates were assigned as aging-
control group (WT group). The EGCG-treated APP/PS1 group
intragastically received EGCG (2mg · kg –1 · day –1) for 4weeks;
the APP/PS1 and WT groups received the same volume of
vehicle for 4 weeks.
Passive Avoidance Test
After 4 weeks of the EGCG treatment, mice were subjected to
a passive avoidance test (PAT), as previously described [31,
32]. The apparatus (BA-200, Chengdu Taimeng Tech. Co.
Ltd., Chengdu, People's Republic of China) consists of two
compartments with a lighted compartment connected to a
darkened one by an automatic guillotine door. The dark com-
partment is equipped with a grid floor placed through which a
foot-shock can be delivered. In the training session, each
mouse was placed in the light compartment and allowed to
explore for 3 min, at which point the guillotine door was
raised to allow the mouse to enter the dark compartment.
When the mouse entered the dark compartment, the guillotine
door was closed and an electrical foot shock (0.5 mA, 1 s
duration) was delivered. Training session was conducted be-
fore the test session. The test session was performed 24 h after
the training session. In the test session, eachmouse was placed
in the light compartment and allowed to explore 3 min, and
then the guillotine door was raised. The latencies and frequen-
cies for mice to enter the dark compartment were recorded
during the whole testing period (300 s).
Morris Water Maze Test
After the PAT, micewere given another behavioral test, Morris
water maze (MWM), for consecutive 7 days including navi-
gation tests and a probe trial test, as previously described with
a few modifications [33, 34].
The Morris water maze is a stainless-steel circular water
tank (120 cm diameter×50 cm height) equipped with a plat-
form (10 cm diameter) placed in the second quadrant and
submerged 0.5–1 cm below the surface of water. In brief,
mice were allowed to swim freely for 1 min without the
platform to adjust themselves to the circumstances at the
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baseline day (day 0). From the first day to the fifth day, the
platform was placed under the water in the tank for navigation
tests, and each mouse was subjected to four trials per day at an
intertrial interval of 60 s for spatial acquisition. Different start
locations were used on each trial. If a mouse failed to find the
platform within 60 s, it would be picked up and placed on the
platform for 60 s. For each trial, the latency and the path length
by which the mouse found the hidden platformwere recorded.
On the sixth day, a probe trial was performed to assess mem-
ory consolidation. In this trial, the platformwas removed from
the tank, and the mice were allowed to swim freely for 60 s.
The start position was a novel one which was 180° from the
original platform position to ensure that the spatial preference
was a reflection of the memory of the goal location rather than
for a specific swim path. The frequency that each mouse
crossed the center of the quadrant (where the platform was
previously located) and the percent of time that each mouse
spent in the quadrant were recorded. All the data were obtain-
ed by a video tracking system (Chengdu Taimeng Tech. Co.
LTD, Chengdu, People's Republic of China).
Locomotivity Test
Locomotivity test were conducted after MWM and PAT using
a locomotivity testing paradigm (ZZ-6 system for mice,
Chengdu Taimeng Tech. Co. Ltd., Chengdu, People's
Republic of China). Briefly, mice were placed in the system
and the exploration was assessed for 10 min. Cages were
routinely cleaned with ethanol following each session. The
locomotivity and the frequency of stand-up for each mouse
were recorded.
Animal Dissection and Tissue Collection
Twenty-four hours after the behavioral tests, half of the mice
(n=5) in each group were anesthetized with sodium pentobar-
bital (50 mg/kg) by intraperitoneal administration and then
transcardially perfused with normal saline followed by 4 %
paraformaldehyde solution. The brains were removed and
postfixed in 4 % paraformaldehyde overnight at 4 °C, and
routine paraffin sections (4 μm) were prepared for TUNEL
staining and immunohistochemistry analysis. The rest half of
the mice in each group were killed by decapitation, and the
brains were rapidly removed and cut sagittally into left and
right hemispheres on an ice-cooled board 24 h after the
behavioral tests. The hippocampus and cerebral cortex were
dissected out and stored at −80 °C for Western blotting
analysis.
Immunohistochemistry
Sections were dewaxed in xylene and rehydrated in a series of
graded alcohols. After dewaxing and rehydration, sections
were boiled in citrate buffer (10 mM, pH 6.0) for 20 min by
microwave oven for antigen retrieval. Then, the sections were
treated with 3 % H2O2 in 0.1 M phosphate buffered solution
(PBS) for 20 min at room temperature to abolish endogenous
peroxidase activity. After washing with PBS, sections were
blocked with normal goat serum at 37 °C for 30 min.
Subsequently, sections were incubated overnight at 4 °C with
primary rabbit anti-caspase 3 antibody (1:500, Abcam), anti-
Aβ antibody and anti-APP antibody (1:500, Thermo). After
rinsing, sections were incubated in biotinylated goat anti-
rabbit IgG (1:200, Maixin) at 37 °C for 30 min, followed by
streptavidin–peroxidase conjugate (1:200, Maixin) at 37 °C
for 30 min. The immunoreactions were visualized by staining
sections with 3′-diaminobenzidine (DAB) for 1–3 min.
Finally, the sections were counterstained with hematoxylin
for 5 min.
TUNEL Staining
TUNEL staining was performed on the paraffin-embedded
sections using the in situ cell death detection kit (Promega,
Madison, USA). According to the standard protocols provided
bymanufacturer, the sections were deparaffined, rehydrated in
graded alcohol series, and treated with 3 %H2O2 for 10 min at
room temperature. Then, these sections were rinsed three
times with PBS, incubated in a 20 μg/ml Proteinase K work-
ing solution for 15 min at 37 °C, and rinsed with PBS thrice
followed by incubation with TUNEL reaction mixture for 2 h
at 37 °C. Biotinylated antidigoxigenin antibody was then
reacted with the sections for 30 min at 37 °C. Apoptotic nuclei
were visualized using the peroxidase-DAB reaction. The sec-
tions were counterstained with hematoxylin. TUNEL-positive
neurons in hippocampus were counted in six random areas of
sections per high-power field (×400), and represented as the
percentage of 100 neurons as the cell apoptosis index.
Fluoro-Jade B Staining
Tissue sections were mounted on 2 % gelatin-coated slides
and then air-dried overnight. The slides were immersed in
100% ethanol for 5 min, 80% ethanol for 5 min, 70% ethanol
for 2 min, and distilled water for 2 min. After incubation in
0.06 % solution of potassium permanganate for 15 min, the
sections were rinsed in distilled water for 2 min, and then
incubated in 0.0004 % Fluoro-Jade B (Chemicon) staining
solution in 0.1 % acetic acid for 30 min, rinsed again in
distilled water for 1 min for three times, and air-dried.
Finally, the dry slides were cleared by immersion in xylene
for 1 min before coverslipping with DPX (Fluka). Fluoro-Jade
B positive cells per square millimeter in hippocampus
were counted in six random areas of sections per high-
power field (×400).
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Image Analysis
Images were obtained using an Olympus BX-61 microscope
and digitized using an attached Spot flex imaging system
(Diagnostic). Images of 4-μm sections through each anatomic
region of interest (hippocampus or cortical areas) were cap-
tured. The related studied indexes were assessed by densito-
metric measurements of product on digitized images. Regions
of interest were identified under dark-field illumination.
Background level was determined from the area outside the
brain section. First-level threshold was determined after
subtracting the background level. The second level threshold
was determined after subtracting nonspecific binding in omit
and negative controls. Thus, the net integrated optical density
representing specific immunoreactive signal was determined
after subtracting first and second level thresholds. Each sam-
ple was digitized under identical illumination, threshold, and
camera settings. The data were analyzed with an image anal-
ysis system (Image-Pro Plus 6.0).
Western Blot
Hippocampus samples were minced into small pieces, ho-
mogenized on ice in precooling RIPA buffer containing
150 mM NaCl, 50 mM Tris–HCl (pH 8.0), 1 % NP-40,
0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate
(SDS), 0.1 % phenylme-thylsulfonyl fluoride, and incubated
overnight at 4 °C. The homogenate was centrifuged at
12,000×g for 30 min at 4 °C, and the supernatant was divided
into aliquots and frozen at −80 °C. Protein qualification was
carried out using a BCA kit (Walterson Biotechnology Inc.,
Beijing, China). The total protein extract (40 μg per lane) was
separated on SDS-polyacrylamide gels, and transferred onto
polyvinylidene difluoride membranes (Millipore, CA).
Nonspecific binding sites on the membrane were blocked by
PBS containing 0.1 % Tween-20 (PBST) with 5 % bovine
serum albumin for 1 h. The membranes were then incubated
overnight at 4 °C with specific primary antibodies. Rabbit
polyclonal antibodies against NGF (1:500, Santa Cruz), APP
and Aβ1-40 (1:1,000, Sigma), TrkA and phospho-TrkA
(Tyr490) (1:1,000, Cell Signaling), c-Raf and phospho-c-Raf
(Ser 338) (1:2,000, Cell Signaling), ERK1/2 and phospho-
ERK1/2(Thr202/Tyr204) (1:2,000, Cell Signaling), cAMP
response element-binding protein (CREB) and phospho-
CREB (Ser 133) (1:1,000, Cell Signaling), p75ICD (1:500,
Santa Cruz), JNK2 and phospho-JNK2 (Tyr 185) (1:1,000,
Cell Signaling), cleaved-caspase 3 (Asp 175) (1:1,000, Cell
Signaling), p53 (1:500, Santa Cruz), and β-actin (1:1,000,
Santa Cruz), were used in this study. After washed with
PBST, the membranes were incubated with goat horseradish
peroxide-conjugated second rabbit anti-body (1:2,000; Santa
Cruz) for 1 h at room temperature. Immunoreactive bands
were visualized using the enhanced chemiluminescent kit
(ECL+, Amersham Biosciences). The bands were measured
using the Quality One analysis software (BioRad), and the
intensity of phophos-immunoreactive protein bands was nor-
malized to total protein. The immunoreactive protein bands of
total protein were normalized to β-actin.
Statistical Analysis
Data were expressed as means±standard deviation (SD). All
statistical analysis was performed using SPSS (Statistical
Package for the Social Sciences, version 13.0) statistical soft-
ware package. Differences among WT, APP/PS1, EGCG-
treated APP/PS1 groups were assessed by one-way ANOVA
followed by Turkey's test. P<0.05 was considered significant.
Results
EGCG Treatment Ameliorated Learning and Memory
Impairment in APP/PS1Mice
To investigate whether EGCG treatment improved learning
and memory in APP/PS1mice, behavioral tests such as PAT,
MWM, and locomotivity test were performed following
EGCG treatment.
In PAT, the learning and memory performance was evalu-
ated by the latency and the frequency of entering the dark
compartment in WT, APP/PS1, and EGCG-treated APP/
PS1groups. Compared with WT group, the latency to enter
the dark compartment in the APP/PS1group was significantly
decreased (P<0.01, Fig. 1a), and the frequency of entering the
dark compartment was increased significantly (P<0.01,
Fig. 1b), suggesting that the learning and memory perfor-
mance of APP/PS1 transgenic mice were impaired.
However, in the EGCG-treated APP/PS1 group, the latency
to enter the dark compartment was apparently increased
(P<0.01, Fig. 1a) and the frequency of entering the dark
compartment was decreased significantly (P<0.01, Fig. 1b)
compared with the APP/PS1 group, suggesting that EGCG
treatment ameliorated the learning and memory impairment in
APP/PS1mice.
Then, theMWM test was conducted. In the navigation tests
of MWM test, on the first day, we observed that the WTmice,
APP/PS1mice and EGCG-treated APP/PS1mice had a sim-
ilar escape latency (P>0.05, Fig. 2a) and path length (P>0.05,
Fig. 2b), indicating that the motility or vision of mice was not
affected before the navigation test and probe trial. In the
navigation tests of the following days (from the second day
to the fifth day), the APP/PS1 group showed higher escape
latency (P<0.01, Fig. 2a), longer path length (P<0.01,
Fig. 2b) and slower improvement than the WT group. While
the escape latency and the path length in the EGCG-treated
APP/PS1group in the navigation training were significantly
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improved, compared with those in the APP/PS1 group
(P<0.01, Fig. 2a and b), suggesting that EGCG treat-
ment improved the impairments of spatial acquisition of
APP/PS1 mice. Moreover, in the probe trial on the sixth
day of MWM tests, the APP/PS1 mice passed through
the original position of the platform with fewer times
(P<0.01, Fig. 3a and c) and had shorter stay in the
target quadrant (P<0.01, Fig. 3a and b) than the WT
group. In the EGCG-treated APP/PS1 group, the time
spent in target quadrant (P<0.01, Fig. 3a and b) and the
frequencies to pass the goal (P<0.01, Fig. 3a and c)
significantly increased compared with the APP/PS1
group. The MWM test results indicated that EGCG
treatment improved the impairments of memory consol-
idation of APP/PS1 mice.
In order to investigate whether the behavioral deficits were
affected by the locomotor activity among different groups, we
studied the locomotivity and the frequencies of stand-up in all
groups. We found that there were no significant differences
among the groups (P>0.05, Fig. 4a and b), suggesting that it
was the memory and learning ability, not locomotivity, con-
tributing to the changes of behavioral deficits in PAT and
MWM.
Thus, these results of behavioral tests demonstrated
that EGCG treatment ameliorated the cognitive deficits
in spatial learning and memory function of APP/PS1
mice.
EGCG Treatment Decelerated Aβ(1–40) Plaque Formation
and Reduced APP Expression in the Brains of APP/PS1Mice
Behavioral test showed that the mice in APP/PS1 group had
impairments of cognition, and the impairments were rescued
with EGCG treatment. Next, we investigated the Aβ(1–40)
plaque formation and APP expression in the APP/PS1 groups
to ensure these mice suffering a similar pathological process
of AD and tested the Aβ(1–40) plaque formation and APP
expression in the EGCG-treated APP/PS1 mice to verify the
effect of EGCG treatment.
The formation level of Aβ(1–40) plaque in the hippocampus
of APP/PS1 mice was measured with imunohistochemistry
methods (Fig. 5a) and Western blot (Fig. 5b). After a 4-week
administration of EGCG, the desposition of Aβ(1–40) plaques in
the EGCG-treated APP/PS1 group was significantly decreased
compared with the APP/PS1group (P<0.01, Fig. 5a), which was
similar with the results of Western blot (P<0.05, Fig. 5b), sug-
gesting that EGCG treatment alleviated the overexpression of
Aβ(1–40) protein in the hippocampus in APP/PS1mice.
Furthermore, as APP is the precursor protein contributed to
Aβ plaque formation associated with AD, we measured APP
expression with immunohistochemistry methods (Fig. 6b) and
Western blot (Fig. 6b) in APP/PS1 mice and WT mice. As
expected, APP/PS1 mice in the APP/PS1 group exhibited
significantly higher expression of APP in hippocampus than
the APP expression in the WT group (P<0.01, Fig. 6a), while
Fig. 1 EGCG treatment
ameliorated the latency (a) and the
frequencies of entering the dark
compartment (b) of APP/PS1
mice in the passive avoidance test
(n=10) **P<0.01, compared with
WT group; ##P<0.01, compared
with APP/PS1 group
Fig. 2 EGCG treatment
improved the escape latency (a)
and path length (b) of APP/PS1
mice in the navigation test of
Morris water Maze (n=10).
*P<0.05, **P<0.01, compared
with WT group; #P<0.05,
##P<0.01, compared with APP/
PS1 group
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EGCG treatment significantly decreased the APP protein level
in the hippocampus of APP/PS1 mice in the EGCG treated
group (P<0.01, Fig. 6b), which were again unanimous with
the results of Western blot (P<0.01, Fig. 6b).
EGCG Treatment Attenuated Neuronal Apoptosis
in the Hippocampus of APP/PS1Mice
Extensive Aβ(1–40) and APP deposits have been reported to
induce neuron damage and neurotoxicity [3, 7, 8]. Next, we
investigated whether the neuronal apoptosis was induced with
overexpressed Aβ(1–40) and APP proteins in the APP/PS1
mice. The sections of the mouse brain were stained with
TUNEL method to detect apoptosis. The number of
TUNEL-positive cells was significantly increased in the hip-
pocampus (P<0.01, Fig. 7) in the APP/PS1 group compared
with those in the WT group. Mice in the EGCG-treated APP/
PS1 group showed fewer TUNEL-positive cells than mice in
the APP/PS1 group (P<0.01, Fig. 7).
As caspase 3 is a typical hallmark of apoptosis, we also
determined the expression levels of caspase 3 by
immumochemical staining for further confirmation. Concord
with the TUNEL results, EGCG-treated APP/PS1 group
showed less expression level of caspase 3 than APP/PS1
group (P<0.01, Fig. 8).
Moreover, we investigated whether EGCG treatment
improved neurodegeneration in the hippocampus of
APP/PS1 mice by a specific method of Fluoro-Jade B
staining for degeneration for triple-check, based on the
findings of TUNEL and caspase 3 immunostaining.
Again, we further found that the increased Fluoro-Jade
B positive cells in hippocampus of APP/PS1 mice were
significantly reduced after EGCG treatment (P<0.01,
Fig. 9).
Consequently, our results above indicated that EGCG treat-
ment inhibited the neuronal apoptosis and neurodegeneration
in the hippocampus of APP/PS1mice.
EGCG Treatment Adjusted the TrkA/p75NTR Balance
by Increasing the Ratio of NGF Versus proNGF
in the Hippocampus of APP/PS1Mice
NGF deficiency triggers the TrkA/p75NTR imbalance,
which then induces apoptosis, neurodegeneration, and
death [35, 36]. Therefore, we tested whether NGF and
proNGF levels were altered in the hippocampus of APP/
PS1 transgenic mice with and without EGCG treatment.
We found that EGCG significantly increased the levels
of both NGF (P<0.01, Fig. 10a) and proNGF (P<0.05,
Fig. 10a) in APP/PS1 mice; furthermore, the ratio of
NGF versus proNGF was also significantly increased in
the EGCG-treated APP/PS1 group (P<0.01, Fig. 10b),
indicating that EGCG mainly ameliorated the NGF star-
vation by increasing NGF level.
Next, we investigated the NGF/TrkA-related signaling
pathway and related substrates downstream in APP/PS1
mice after EGCG treatment. After EGCG treatment, the
phosphorylated protein levels of TrkA (P<0.01,
Fig. 11a), c-Raf (P<0.01, Fig. 11b), ERK1/2 (P<0.01,
Fig. 11c), and CREB (P<0.01, Fig. 11d) were increased,
and the total protein levels were unchanged in the
EGCG-treated APP/PS1 group (P>0.05, Fig. 11a–d),
compared with the APP/PS1 group, indicating that
Fig. 3 EGCG treatment improved the performance of the probe trial in
Morris water maze of APP/PS1mice (n=10). aThe representive locus plot
after EGCG treatment in the probe trial. b EGCG treatment prolonged the
time spent in target quadrant. cEGCG treatment increased the frequencies
of passing through the goal. *P<0.05, **P<0.01, compared with WT
group; #P<0.05, ##P<0.01, compared with APP/PS1 group
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EGCG treatment activated the TrkA receptor and its
downstream ERK signaling pathway by increasing
NGF relative expression, and induced the activation of
CREB, an important molecule for amyloidosis, learning,
and memory.
Moreover, the NGF/p75NTR related signaling pathway and
substrates downstream in APP/PS1 mice after EGCG treat-
ment were also investigated in the present study. The cleavage
activity of p75NTR (P<0.01, Fig. 12a), the phosphorylation of
JNK2 (P<0.01, Fig. 12b), and the expression levels of p53
Fig. 4 EGCG treatment did not
affect locomotivity (a) and the
frequencies of stand-up (b) of
APP/PS1 mice in locomotivity
test (n=10). P>0.05 among all the
groups
Fig. 5 EGCG treatment
ameliorated the overexpression of
Aβ(1–40) in the hippocampus of
APP/PS1mice by
immunohistochemical staining (a)
and Western blot (b) (n=5).
**P<0.01, compared with WT
group; ##P<0.01, compared with
APP/PS1 group
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Fig. 6 EGCG treatment
decreased the APP expression
levels in the hippocampus of
APP/PS1mice by
immunohistochemical staining (a)
and Western blot (b) (n=5).
**P<0.01, compared with WT
group; ##P<0.01, compared with
APP/PS1 group
Fig. 7 EGCG treatment
ameliorated the neural apoptosis
in the hippocampus of APP/PS1
mice by TUNEL staining (n=5).
Red arrow indicated the TUNEL
positive cell. *P<0.05,
**P<0.01, compared with WT
group; #P<0.05, ##P<0.01,
compared with APP/PS1 group
Mol Neurobiol (2014) 49:1350–1363 1357
(P<0.01, Fig. 12c) and cleaved-caspase 3 (P<0.01,
Fig. 12d) were all reduced after EGCG treatment, com-
pared with the mice in APP/PS1 group. These results
suggested that EGCG inhibited the NGF/p75NTR related
signaling concurring with the activiation of NGF/TrkA
related signaling, and then decreased the expression
levels p53 and cleaved-caspase 3, and finally inhibited
the neuronal apoptosis.
Discussions
The APP/PS1 transgenic mouse model mimics the patholog-
ical and behavioral changes of AD based on amyloid hypoth-
esis. APP/PS1 transgenic mice have early onset time and
intensive degree of Aβ despoition, following with neuronal
loss and cognitive impairment. It is a reliable, powerful model
for AD research [37]. Green tea and its polyphenolic
Fig. 8 EGCG treatment
decreased the expression level of




compared with WT group;
#P<0.05, ##P<0.01, compared
with APP/PS1 group
Fig. 9 EGCG treatment
improved neurodegeneration in
the hippocampus of APP/PS1
mice by Fluoro-Jade B staining
(n=3). *P<0.05, **P<0.01,
compared with WT group;
#P<0.05, ##P<0.01, compared
with APP/PS1 group
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ingredients EGCG have been suggested to possess neuropro-
tective effects in vitro [23–25], Lee et al. [25], Rezai-Zadeh
et al. [26], and He et al. [27] reported that EGCG treatment
significantly improved the cognitive deficits, APP processing,
and Tau pathology in D-gal-induced AD mice, TgAPPsw line
2576 transgenic mice, and PS2 transgenic mice. Jia et al. [38]
recently also reported that EGCG improved memory
deficits by decreasing the phosphorylation level of
IRS-1; however, the neuroprotective mechanism of
EGCG is still puzzled. Our results showed that EGCG
treatment improved the memory and learning impair-
ment in APP/PS1 mice in PAT and MWM tests
(Figs. 1, 2, and 3), decreased the expressional levels
of APP and Aβ(1–40) (Figs. 5 and 6) and also allevi-
ated the neuronal apoptosis and neurodegeneration
(Figs. 7, 8, and 9), indicating that EGCG treatment
ameliorated the cognitive deficits in APP/PS1 transgenic
mice. These results were consistent with reports in other
AD mouse models including models induced by D-gal,
lipopolysaccharide, or Aβ(1–42), and PS2 transgenic
mouse model [24, 39–41]. Recent studies revealed that
it was the TrkA/p75NTR balance contributing to the final
pharmacological effects of NGF [14–16]. Therefore, we
evaluated and confirmed the important role of
TrkA/p75NTR balance in the EGCG-induced neuropro-
tective effects. It is the first study to reveal that the
EGCG-induced neuroprotective effect is through modu-
lating TrkA/p75NTR balance.
NGF is proposed as a functional neurotrophin stimulating
cell differentiation, development, survival, and plasticity of
neurons, and inhibiting apoptosis to exert nutrient and
supportive effects [10, 16]. It is known that NGF elicits the
survival and proliferative effects by activating the NGF/
TrkA signaling, and at the same time, the NGF/p75NTR
signaling is suppressed by the TrkA activation to elicit the
anti-apoptosis effects. On the contrary, proNGF, a precur-
sor protein of NGF, elicits the opposite effects such as
neuron loss and apoptosis by p75NTR activation [14, 15].
Casponi et al. [42] found that as NGF was neutralized by
the recombinant antibody in AD11 anti-NGF transgenic
mice, the proNGF was predominant, which led to
p75NTR-dependent apoptosis and cognitive deficits. The
p75NTR-dependent apoptosis and cognitive deficits could
be fully reverted by NGF administration. Therefore, the
relative expression level of NGF and proNGF (that is, the
ratio of NGF versus proNGF) was a key point for main-
taining the TrkA/p75NTR balance. The present study
showed that the NGF expression level was significantly
decreased (shown in Fig. 10a), and the ratio of NGF
versus proNGF was also reduced (shown in Fig. 10b),
suggesting that the TrkA/p75NTR imbalance caused by
NGF deficiency occurred in the APP/PS1 mice. EGCG
treatment significantly increased both NGF level and the
ratio of NGF versus proNGF, indicating that EGCG treat-
ment elicited the neuroprotective effects by adjusting the
TrkA/p75NTR imbalance.
Furthermore, we examined the TrkA signaling and the
effective substrates downstream. We found that EGCG treat-
ment ameliorated the NGF deficiency, subsequently increased
the phosphorylation of TrkA receptor, activated NGF/TrkA
singnaling, and increased the phosphorylation of c-Raf,
ERK1/2 (shown in Fig. 11). These results agree with a recent
Fig. 10 MEM treatment elevated
the expression levels of NGF and
its precursor neurotrophin
proNGF (a), and increased the
relative expression level of NGF
versus proNGF (b) in the
hippocampus of APP/PS1 mice
(n=3). *P<0.05, **P<0.01,
compared with WT group;
#P<0.05, ##P<0.01, compared
with APP/PS1 group
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report by Williams et al. They found that, after NGF
injection, TrkA level was increased in basal forebrain,
and then MAPK pathways was activated with the phos-
phorylation of ERK without changing the total ERK level,
which indicated a possible mechanism of NGF signaling
associated with aging-related memory loss in the CNS
[43]. We also found that EGCG treatment increased the
phosphorylation of CREB by activating NGF/TrkA signal-
ing, in accord with the results of Autio et al. [44] that
acetylcholinesterase inhibitors donepezil and galantamine
increased the phosphorylation of TrkA and CREB. The
activation and phosphorylation of CREB also inhibit the
Aβ oligomerization and formation and decrease the Aβ
neurotoxicity [45, 46]. In addition, CREB activation also
reduced the messenger RNA and protein expression of γ-
secretase in APP processing [47], which in turn attenuated
the formation of Aβ. The attenuation of Aβ formation
then ameliorated the LTP deficits and cognitive impair-
ment and increased the synaptic plasticity [48]. Therefore,
The activation and phosphorylation of CREB was associ-
ated with APP processing and Aβ desposits, which had
the same tendency with our results that phosphorylation of
Fig. 11 MEM treatment
activated NGF-TrkA signaling by
increasing the phosphorylation
levels of TrkA (a), c-Raf (b), and
ERK1/2 (c), finally upregulated
the phosphorylation level of the
CREB (d) downstream, which
was closely related with memory
and learning in the hippocampus
of APP/PS1 mice byWestern blot
(n=3). **P<0.01, compared with
WT group; ##P<0.01, compared
with APP/PS1 group
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CREB was related with the decreased levels of APP and
Aβ (shown in Figs. 5 and 6). Moreover, Matrone et al.
[49] found that NGF induced phosphorylation of APP by
TrkA and regulated NGF/TrkA signaling, and consequen-
tially affected the differentiation and survival of neurons.
Therefore, NGF had close relationship with APP and Aβ
deposits. Our results that EGCG treatment increased NGF
level, decreased the expression levels of APP and Aβ(1–
40), and ameliorated cognitive impairment were consistent
with these observations.
Lastly, we found that EGCG decreased the cleavage activ-
ity of p75NTR and inhibited the activation of NGF/p75NTR
signaling; then inhibited the JNK signaling and decreased the
expression levels of p53 and cleaved-caspase 3 (shown in
Fig. 12); and finally inhibited the neuronal apoptosis (shown
in Figs. 7, 8, and 9). These results were in accord with the
researches on p75NTR signaling by Hashimoto et al. [50] and
Costantini et al. [13], and verified the results proposed by
Song et al. and Fortress et al [14, 15] that NGF/TrkA signaling
and NGF/p75NTR signaling were inhibited by each other.
In conclusion, EGCG treatment activated the TrkA signal-
ing, inhibited the p75NTR signaling, and adjusted the
TrkA/p75NTR imbalance by increasing the NGF relative ex-
pression inAPP/PS1mice to ameliorate the behavioral deficits
and amyloidosis. These results suggested that EGCG is a
potential therapeutic agent to provide beneficial effects on
aging and AD.
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Fig. 12 MEM treatment
inhibited the cleavage ability of
p75NTR and its related signaling
by decreasing the cleavage
product p75ICD (a), reducing the
phosphorylation of JNK2 (b), so
as to decreasing the target
substrates downstream p53 (c)
and cleaved-caspase 3 (d) in the
hippocampus of APPcxxPS1mice
byWestern blot (n=3). **P<0.01,
compared with WT group;
##P<0.01, compared with APP/
PS1 group
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